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Abstract Myosin-7a participates in auditory and visual
processes. Defects in MYO7A, the gene encoding the
myosin-7a heavy chain, are causative for Usher syndrome
1B, the most frequent cause of deaf-blindness in humans.
In the present study, we performed a detailed kinetic and
functional characterization of the isolated human myosin-
7a motor domain to elucidate the details of chemome-
chanical coupling and the regulation of motor function. A
rate-limiting, slow ADP release step causes long lifetimes
of strong actin-binding intermediates and results in a high
duty ratio. Moreover, our results reveal a Mg
2?-sensitive
regulatory mechanism tuning the kinetic and mechanical
properties of the myosin-7a motor domain. We obtained
direct evidence that changes in the concentration of free
Mg
2? ions affect the motor properties of human myosin-7a
using an in vitro motility assay system. Our results suggest
that in a cellular environment, compartment-speciﬁc ﬂuc-
tuations in free Mg
2? ions can mediate the conditional
switching of myosin-7a between cargo moving and tension
bearing modes.
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Abbreviations
Dd Dictyostelium discoideum
dmADP Desoxy-mantADP
dmATP Desoxy-mantATP
DTT 1,4-Dithiothreitol
EYFP Enhanced yellow ﬂuorescent protein
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic
acid
LDH Lactate dehydrogenase
mant N-methylanthraniloyl
MOPS 4-Morpholinepropanesulfonic acid
PEP Phosphoenolpyruvate
PK Pyruvate kinase
RPE Retinal pigment epithelial
Sf9 Spodoptera frugiperda
TRITC Tetramethylrhodamine isothiocyanate
Introduction
Myosin is a mechanoenzyme that uses actin-activated ATP
turnover to power interactions with actin ﬁlaments pro-
ducing force and/or driving directed movement. Class 7
myosins form one of the 12 myosin classes found in
humans [1]. They are among the most widely produced
myosins in the animal kingdom and display broad tissue
expression [2–4]. Two distinct class 7 myosins are pro-
duced in humans. The myosin-7a and myosin-7b heavy
chains are encoded by MYO7A and MYO7B, and display
distinct kinetic and functional properties. The human
myosin-7a heavy chain is composed of the N-terminal
motor domain, a neck region with 5 IQ motifs, and a
complex tail region. The tail region contains a SAH
domain (absent in vertebrate myosin-7b), a *460 amino
acid segment formed by a myosin tail homology 4
(MyTh4) domain and a band 4.1-ezrin-radixin-moesin
(FERM) domain, an SH3 domain, and a second, C-terminal
MyTH4-FERM tandem domain [2, 5–7]. Myosin-7a
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123activity is regulated by an interaction between the tip of the
tail and the motor domain [8]. Moreover, the SAH domain
acts as a lever arm extension [8]. It has been suggested that
myosin-7 functions by exerting local tension, especially at
the plasma membrane, and moving cargos. Myosin-7a was
found to associate with lysosomes and may be involved in
lysosome trafﬁcking [9]. However, most studies of myosin-
7a function focused on its role in auditory and visual
processes.
In the auditory apparatus, myosin-7a is produced in
cochlear mechanosensory stereocilia of the hair cells, where
it is involved in hair bundle morphogenesis and mechano-
transduction [10–12]. Additionally, myosin-7a motor
activity contributes to processes such as differentiation and
organization of hair cell stereocilia [12]. Within the neu-
roretina, myosin-7a is involved in the distribution and
migration of retinal pigment epithelial (RPE) melanosomes
and phagosomes [13, 14], and enables the regulation of
opsin transport in retinal photoreceptors [15, 16]. Mutations
in MYO7A are associated with several forms of inherited
deafness and deaf-blindness in both humans and mice [17,
18]. MYO7A mutations are causative for hearing impair-
ment and vestibular dysfunction in Usher syndrome type 1B
(USH1B), the major cause of deaf-blindness in humans, and
are linked to non-syndromic hearing loss (DFNB2,
DFNA11) [17, 19]. The murine orthologue of MYO7A is
causative for the shaker-1 phenotype [18].
At the protein level, the central SAH domain forms a
stable single a-helix and acts as a lever arm extension,
rather than dimerizing two myosin molecules as previously
proposed [8]. Isolated molecules of Drospohila myosin-7a
are monomeric [8], which raises the possibility that the
human orthologue is a single-headed molecular motor as
well [20]. The motor properties of human myosin-7a are
largely unknown. In the present study, we produced the
motor domain of human myosin-7a fused to an artiﬁcial
lever arm and an EYFP ﬂuorescence marker (M7a). We
used construct M7a to analyze the kinetic and functional
properties of the myosin-7a motor domain. Our results
show that human myosin-7a is a slow motor with a rate-
limiting ADP release step from actomyosin and a high
afﬁnity for F-actin, even in the presence of ATP. Addi-
tionally, we report a Mg
2? ion-sensitive regulatory
mechanism affecting ATP turnover, ADP release kinetics
from actomyosin, and motor activity.
Materials and methods
Reagents
TRITC-phalloidin was purchased from Sigma-Aldrich; His
antibody and Ni
2?-NTA were from QIAGEN. Restriction
enzymes,polymerases,LRandBPClonaseenzymemixture,
and DNA-modifying enzymes were purchased from MBI-
Fermentas, Finnzymes, and Invitrogen. Other enzymes and
protease inhibitor cocktail tablets were from Roche Applied
Sciences. Standard reagents were from Sigma-Aldrich.
Construction of baculovirus transfer vectors
The myosin-7a construct was cloned by fusing the human
myosin-7a motor domain (amino acids 1–747) with an
artiﬁcial lever arm (named ‘‘2R’’) and an EYFP ﬂuores-
cence marker. A C-terminal His8-tag enables Ni
2?-chelate
afﬁnity chromatography. The molecular mass of the fusion
construct was calculated to be 142 kDa from amino acid
sequence. The human myosin-7a cDNA clone pCMV-
Sport6-Myo7a was a generous gift of Dr. D.S. Williams
(UCSD School of Medicine, La Jolla, CA). The motor
domain of human myosin-7a was subcloned into pGEM-T-
Easy using a pair of primers. The motor domain was
ampliﬁed using the primers 5REC-M7MDH8 (GGG GAC
AAG TTT GTA CAA AAA AGC AGG CTC CGG ATC
CAT GGT GAT TCT TCA GCA GGG G) and 3REC-
M7MDH8 (GGG GAC CAC TTT GTA CAA GAA AGC
TGG GTC ATC TCG AGT GTC GGT GAT GGC TTT
GTC CCG). The PCR fragment was used in the BP
recombination according to the manufacturer (Invitrogen)
with the vector pDONR201. The entry vector was used in a
LR recombination reaction with the vector pDEST8
according to the manufacturer’s instruction. The motor
domain construct fused to the 2R-EYFP unit was obtained
by insertion of the 2R-EYFP-His8 cassette from the vector
pDONR201-2R-EYFP-His8 in frame with the myosin
motor domain by digestion with XhoI. The transfer vector
was conﬁrmed by sequencing.
Production and preparation of recombinant protein
The myosin fusion protein was overproduced using the
baculovirus/Sf9 system. Therefore, the transfer vector was
transformed in DH10Bac E. coli cells to generate recom-
binant bacmid. Bacmid was isolated and transfected in Sf9
insect cells using Cellfectin II (Invitrogen). Recombinant
baculovirus was produced as described by the manufac-
turer. Sf9 cells were infected with recombinant baculovirus,
collected 72 h post infectionem and stored at -80 C.
For puriﬁcation, cells were lysed [50 mM HEPES (pH
7.3), 300 mM NaCl, 3 mM MgCl2, 2 mM ATP, 10 mM
b-mercaptoethanol, 4 mM imidazole, in the presence of
protease inhibitors], ultracentrifuged (138,0009g, 35 min)
and the extract applied to a Ni
2?-afﬁnity column. The resin
was washed with ATP buffer (25 mM HEPES (pH 7.3),
600 mM NaCl, 0.5 mM ATP, 0.1 mM EGTA, 3 mM
MgCl2, 20 mM imidazole, 7 mM b-mercaptoethanol, 1%
300 S. M. Heissler, D. J. Manstein
123triton X-100), wash buffer 1 [25 mM HEPES (pH 7.3),
300 mM NaCl, 0.1 mM EGTA, 3 mM MgCl2,4 0 m M
imidazole], and wash buffer 2 [25 mM HEPES (pH 7.3),
500 mM NaCl, 0.1 mM EGTA, 3 mM MgCl2,6 5 m M
imidazole]. The protein was eluted using an imidazole
gradient (100–850 mM) and dialyzed against 25 mM
HEPES (pH 7.3), 400 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1 mM DTT, and 3% trehalose. After gel ﬁltration
(column Superdex 26/60–200 prep grade, Amersham
Pharmacia), the protein was supplemented with 10% tre-
halose, ﬂash frozen, and stored at -80 C.
Active site titration in the absence of F-actin using
mantATP as a substrate was employed to determine the
concentration of active myosin motors. The active motor
concentration was typically *50%. Concentrations repor-
ted in ﬁgure legends and throughout the text are ﬁnal
active-site concentrations. Rabbit skeletal muscle actin was
prepared as described by Lehrer and Kerwar [21] and
labeled with pyrene iodoacetamide as described previously
by Criddle et al. [22]. TRITC-phalloidin labeling was
carried out as reported [23].
Enzyme kinetics
Steady-state kinetics were performed at 25 C with the
NADH-coupled assay in a buffer containing 25 mM
HEPES (pH 7.4), 5 mM MgCl2, 0.5 mM DTT, 0.2 mM
NADH, and an ATP regeneration system consisting of
0.05 mg/ml PK, 0.5 mM PEP, 0.02 mg/ml LDH, and
2 mM ATP. The myosin concentration was 0.15–0.5 lM.
The F-actin concentration was varied between 0 and
100 lM. NADH oxidation was followed using the change
in the absorption at 340 nm (e = 6220 M
-1 cm
-1)i na
temperature-controlled plate reader (MULTISKAN FC,
Thermo) using UV-transparent microtiter plates. The
ATPase activity in the absence of F-actin was subtracted
from the actin-activated data.
Stopped-ﬂow techniques were employed to study the
interaction of myosin with nucleotides and F-actin. Stop-
ped-ﬂow measurements were conducted at 20 C with a
Hi-tech Scientiﬁc SF-61SX2 stopped-ﬂow system equipped
with a 75 W mercury-xenon arc lamp in MOPS buffer
[25 mM MOPS (pH 7.0), 100 mM KCl]. Magnesium
concentrations were adjusted by supplementing MgCl2 to
the MOPS buffer. Free Mg
2? ion concentration was cal-
culated using the Maxchelator software as described
previously [24].
Pyrene ﬂuorescence was excited at 365 nm and moni-
tored through a KV389 cutoff ﬁlter. Intrinsic tryptophan
ﬂuorescence was excited at 297 nm, and emission was
selected using a WG320 cutoff ﬁlter. Mant nucleotides
were excited either directly at 365 nm or excited via
energy transfer from tryptophan (excitation at 297 nm),
and the emitted light was detected after passage through a
KV389 cutoff ﬁlter. Changes in light scattering were
monitored at 90  to the incident light by using an excita-
tion wavelength of 320 nm. Data storage and initial ﬁtting
were performed using the software Kinetic Studio 1.08
(TgK Scientiﬁc). Unless stated otherwise, the reactant
concentrations stated throughout the text are those after 1:1
mixing in the stopped-ﬂow spectrophotometer. Analysis of
kinetic data was accomplished using the same basic
models that were developed to describe the kinetic
behavior of rabbit fast skeletal muscle myosins and other
myosins based on that of Bagshaw et al. [25–28]. Con-
sistent with these models, kinetic parameters for the
interaction of M7a with nucleotide and F-actin were ana-
lyzed in terms of the kinetic model shown in Scheme 1
[28, 29]. The abbreviations used are as follows: A =
F-actin, M = myosin, Pi = inorganic phosphate. The
predominant ﬂux of the reaction pathway is highlighted in
grey. Rate constants are referred to as k?n and k-n,
respectively. Dissociation equilibrium constants are deno-
ted as Kn. Bold notation (Kn, k1n) represents the kinetic
constants in the presence of F-actin. Subscript A and D
refer to actin and ADP, respectively. KA represents the
afﬁnity of myosin for F-actin, KD the afﬁnity of ADP for
myosin, KAD the afﬁnity of ADP for the actomyosin
complex, and KDA the afﬁnity of actin for myosin in the
presence of saturating [ADP]. The asterisk (*) symbol
represents changes in ﬂuorescence intensity.
Myosin motor activity
Actin-sliding motility was measured as described previ-
ously [30] in buffer containing 25 mM imidazole (pH 7.4),
25 mM KCl, 1 mM MgCl2, 1 mM EGTA, 4 mM ATP, and
an oxygen scavenging system consisting of 0.1 mg/ml
glucose oxidase, 0.02 mg/ml catalase, and 5 mg/ml glu-
cose. The experiment was performed at 30 C controlled by
an enclose box on an Olympus IX70 microscope. The
speed of actin ﬁlament sliding was tracked with the help of
the program DiaTrack 3.01 (Semasopht, Switzerland). Data
analysis was performed with Origin 8.0 (OriginLab, USA).
Goodness-of-ﬁt criteria were evaluated using the coefﬁ-
cient of determination R
2 and v
2 tests as implemented in
Origin 8.0.
Scheme 1
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Design, expression, and puriﬁcation of human myosin-
7a motor domain construct
To examine the enzymatic and mechanical properties of the
myosin-7a motor, we designed and produced a recombi-
nant construct containing the catalytically active human
myosin-7a motor domain fused to an artiﬁcial lever arm
and an EYFP ﬂuorescence marker. The artiﬁcial lever arm
comprises two spectrin-like repeats from Dd a-actinin and
functionally replaces the native light chain-binding region
[30]. This protein engineering approach directly links the
myosin core region to the artiﬁcial lever arm, resulting in
the production of the single-headed, constitutively active
myosin constructs with similar kinetic and functional
properties compared to S1-like myosin constructs [30–32].
Crystallographic and functional studies show that the arti-
ﬁcial lever arm used in the present study forms a rigid and
elongated structure that can functionally replace the native
myosin lever arm [32, 33]. The fact that the myosin motor
domain constructs bearing artiﬁcial lever arms can be
produced and puriﬁed in large amounts makes them ideally
suited for systematic studies of the structure, kinetics, and
function of myosin motors from a wide range of classes
and organisms [24, 31, 33–36]. In the case of the human
myosin-7a motor domain construct M7a, the presence of
the EYFP ﬂuorescence marker attached to the C-terminus
of the artiﬁcial lever arm led to a further tenfold increase in
puriﬁcation yields.
Steady-state ATPase activity
We measured the basal ATPase activity of M7a as a
function of [ATP] in the presence of an ATP-regenerating
system. The plot of the observed ATPase rate versus [ATP]
varies hyperbolically with the nucleotide concentration
and gives a plateau value of 0.05 ± 0.01 s
-1 that corre-
sponds to kbasal. Half-maximal activation occurred at
11.69 ± 1.77 lM ATP (Fig. 1a and Table 1). In the pres-
ence of saturating [F-actin], the ATPase activity of M7a
displays a hyperbolic dependence on [ATP] and gives a
value of 0.35 ± 0.01 s
-1 for the maximum activity
(kcat,ATP) with half-saturation occurring at 62.65 ± 7.09
lM( KATP).
Figure 1b depicts the actin-activated ATPase activity of
M7a as a function of [F-actin]. A hyperbolic ﬁt to the data
set gives a maximum actin-activated ATPase activity (kcat)
of 0.35 ± 0.03 s
-1. Half-maximal activation (Kapp,actin)
occurred at an F-actin concentration of 8.3 ± 2.6 lM. The
apparent second order rate constant for F-actin binding
(kcat/Kapp,actin) is 0.04 ± 0.02 lM
-1 s
-1 (Table 1). Com-
parable values of the [F-actin] dependence of the steady-
state ATPase were reported previously [37] and are sum-
marized together with the determined constants of the
present study in Table 1.
Actin interaction
Binding of the M7a construct to pyrene-labeled F-actin
quenches the pyrene ﬂuorescence. The transient decrease of
pyreneﬂuorescence uponmixing M7awithpyrene-actinina
stopped-ﬂowspectrophotometerfollowsamono-exponential
Fig. 1 Steady-state ATPase activity. a Dependence of the basal
steady-state ATPase activity of the myosin-7a motor on [ATP]. A
hyperbolic ﬁt to the data set (ATPase activity = (kbasal[ATP])/
(Kapp,actin ?[ATP])) gives a value for maximal ATPase turnover
(kbasal) as 0.05 ± 0.01 s
-1. Inset, close-up view of the data in the
concentration range between 0 and 500 lM ATP. b Dependence of the
steady-state ATPase activity of the human myosin-7a motor domain as
a function of [F-actin]. The solid curve is a hyperbolic ﬁt (ATPase
activity = (kcat[F-actin])/(Kapp,actin ? [F-actin])) giving kcat and Kapp,
actin values of 0.35 ± 0.03 s
-1 and 8.3 ± 2.6 lM, respectively. The
displayed data for the actin-activated steady-state ATPase activity are
corrected for the basal ATPase activity. Error bars in panels A and B
represent standard deviations from at least 6 determinations of each
data point. The experimental conditions were as follows: 25 mM
HEPES (pH 7.4), 5 mM MgCl2, 0.5 mM DTT, and 2 mM ATP in the
presence of an ATP regeneration system at a temperature of 25 C
302 S. M. Heissler, D. J. Manstein
123decay (Fig. 2a, inset). A secondary plot of the observed rate
constants(kobs)againstthepyrene-actinconcentrationshows
a linear dependence. This is compatible with a simple one-
step binding process, where kobs = [A] k1A ? k2A
(Scheme 1)[38].Thevalueforthesecondorderrateconstant
ofpyrene-actinbindingk1Aisgivenbytheslopeoftheplotas
3.17 ± 0.06 lM
-1 s
-1.Theintercept, k2A, wastoosmall to
deducean accurate value.In thepresence of ADP,the rate of
actin binding isreduced more thantenfoldformany myosins
[28]. When we performed the experiment with M7a in the
presenceofsaturatingconcentrationsofADP,the kobsvalues
were reduced but only to a smaller extent. In this case
kobs = [A] k1DA ? k2DA. The slope obtained from the
correspondingsecondaryplotofthedataindicatesathreefold
reduction in the rate of actin binding (Fig. 2a).
Determination of the rate constants of M7a dissociation
from pyrene-labeled F-actin in the absence (k2A) and
presence (k2DA) of saturating ADP (250 lM) was mea-
sured by chasing pyrene-actin with an excess of unlabeled
F-actin. The observed processes could be ﬁt to single
exponentials where kobs corresponds directly to the rates of
actin dissociation with values of 0.002 ± 4 9 10
-5 s
-1 for
k2A and 0.003 ± 1 9 10
-4 s
-1 for k2DA. A typical time
course for the dissociation from pyrene-labeled F-actin in
the presence of ADP is shown in Fig. 2b. In the absence of
ADP, the ratio of the experimentally determined binding
and dissociation rate constants (k2A/k1A) gives a value of
0.63 nM for the dissociation equilibrium constant for
F-actin binding (KA). In the presence of ADP, the afﬁnity
of M7a for F-actin (KDA = k2DA/k1DA) is 2 nM.
ATP binding to myosin-7a and ATP-induced
dissociation of actomyosin-7a
We monitored binding of ATP to the M7a by the
enhancement of intrinsic tryptophan ﬂuorescence following
the addition of excess ATP. A 5% increase in ﬂuorescence
is observed with M7a. The observed process could be ﬁt to
a single exponential [F = F? (1  ekobst)]. The observed
rate constants measured at different ATP concentrations
are linearly dependent on the concentration of ATP up to
20 lM, with the slope deﬁning an apparent second order
binding constant K1k?2 of 0.85 ± 0.02 lM
-1 s
-1.A t
higher ATP concentrations, up to a maximum of 0.5 mM,
this dependence can be ﬁt to a hyperbola (kobs = kmax
[ATP]/([ATP] ? K0.5)), saturating at a rate of 23.34 ±
0.74 s
-1 (Fig. 3a). K0.5 in this case simply deﬁnes the ATP
concentration at which K1k?2 [ATP] approximately equals
(k?3?k-3)/2. In fact, if ATP binding is rapid and irre-
versible, as expected by analogy with Dd myosin-2 or
skeletal muscle subfragment-1, a hyperbolic function is not
expected (Scheme 1). The good ﬁt to a hyperbola is partly
due to the small change in ﬂuorescence observed on ATP
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123binding for M7a. As the hyperbolic ﬁt probably has no real
meaning, only the second order rate constants at low ATP
concentrations and the plateau values are quoted in
Table 2. For Dd myosin-2 the plateau has been assigned to
the rate constant for the conformational change that limits
the ATP cleavage step (k?3?k-3) and the second order rate
constant to K1k?2 [25, 28, 39]. We assume the same
assignment holds for M7a.
Fig. 2 Interaction of the myosin-7a motor with F-actin in the absence
of nucleotide and in the presence of ADP. a Binding of the human
myosin-7a motor domain to pyrene-actin ﬁlaments in the absence
(ﬁlled circle) and presence (open circle) of saturating ADP (250 lM).
The concentration of the M7a construct was kept at 1:5 to 1:7.5 of the
pyrene-actin concentration. The rate of pyrene-actin quenching is
linearly dependent on [pyrene-actin] up to 1.75 lM. The apparent
second order rate constants derived from the slopes of linear ﬁts to the
data sets are k1A = 3.17 ± 0.06 lM
-1s
-1 and k1DA = 1.34 ±
0.03 lM
-1s
-1, respectively. Inset, time course upon mixing M7a
(0.125 lM) with an excess of pyrene-actin (0.75 lM) approximated
with a single exponential equation. Time axes are identical for the
data ﬁts and the corresponding residual plot. Error bars represent
standard deviations from at least three determinations of each data
point. b Chase experiment of the ternary pyrene-acto•M7a•ADP
complex (0.25 lM) with excess of unlabeled F-actin (20 lM). A
single exponential ﬁt to the transient shown gives a value for k2DA as
0.003 ± 1.10
-4 s
-1. Time axes in the data ﬁt and the corresponding
residual plot (inset) are the same. Experimental conditions were as
follows: 20 C, 25 mM MOPS (pH 7.0), 100 mM KCl, 5 mM MgCl2,
and 10 mM DTT. Nucleotide-free samples were prepared by prein-
cubation of the reactants with 0.1 U/ml apyrase for 15 min at room
temperature
Fig. 3 ATP binding to myosin-7a motor and ATP-induced dissoci-
ation of actomyosin-7a. a ATP binding to myosin-7a motor was
followed in a stopped-ﬂow apparatus by the change in intrinsic
ﬂuorescence signal. A plot of the observed rate constants versus
[ATP] shows a hyperbolic dependence converging at a rate of
k3 ? k-3 = 23.1 ± 0.74 s
-1. Inset, ATP binding to myosin-7a motor
monitored by tryptophan and mantATP ﬂuorescence. Rate of ATP
(ﬁlled circle) and mantATP (open circle) binding to myosin-7a motor
domain as a function of nucleotide concentration. The solid lines
correspond to the linear ﬁt of the initial slopes and deﬁne the second
order rate constant for ATP (K1k?2 = 0.85 ± 0.02 lM
-1 s
_1) and
mantATP (K1k?2 = 1.15 ± 0.01 lM
-1 s
_1) binding to the myosin-7a
motor. b ATP-induced dissociation of the preformed actomyosin-7a
complex. Light-scattering transients were obtained by mixing acto-
myosin-7a with varying [ATP] under pseudo-ﬁrst order conditions. A
hyperbolic ﬁt to the data set converges k12 = 186 ± 5.7 s
-1 with
half-saturating ATP concentration 1/K1 = 681.19 ± 5.63 lM. Inset,
ATP (ﬁlled circle) and mantATP (open circle) binding to actomyosin-
7a. The apparent second order binding rate constants (K1k12) were
deduced from the slopes of the linear approximations and are listed in
Table 2. Error bars in panels a and b represent standard deviations
from at least three determinations of each data point
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123Alternatively, binding of the substrate mantATP was
monitored from the 2.3-fold increase in ﬂuorescence
observed upon addition of substoichiometric concentra-
tions of mantATP to the myosin-7a motor domain
construct. The observed process was analyzed as described
for ATP binding, giving a similar second order rate con-
stant K1k?2 of 1.15 ± 0.01 lM
-1 s
-1 from the initial slope
(Fig. 3a, inset and Table 2).
The ATP-induced population of weakly bound
acto•M7a states was determined by monitoring the
decrease in the light-scattering signal. The process was
modeled as a two-step binding reaction [40]. The time
courses of the reduction in light scattering intensity follow
single exponentials with an additional lag phase. As
depicted in Fig. 3b, the [ATP]-dependence of the observed
rate constants was ﬁt to a hyperbola as predicted from
Scheme 1. The maximum rates of dissociation measured
allow the determination of the rate constant for the fast
isomerization process k12 of 186 ± 5.7 s
-1. The half-
maximal rate of dissociation was reached at 681.19 ±
5.63 lM ATP and represents the apparent equilibrium
constant for ATP binding (1/K1). The rate constant for ATP
binding to the rigor complex (K1k12) was determined at
low [ATP] by following the change in the intensity of light
scattering. The observed rate constants depend linearly on
the [ATP] up to 12.5 lM. The apparent second order
binding rate constant K1k12 of 0.44 ± 0.01 lM
-1 s
-1 was
deduced from the slope of a linear regression (Fig. 3b,
inset). Additionally, we used the increase in the ﬂuores-
cence intensity of the nucleotide analogue mantATP to
determine the rate constants of ATP binding to acto•M7a.
When mantATP was mixed with the rigor complex, a
K1k12 of 0.68 ± 0.01 lM
-1 s
-1 was derived from the
initial slope (Fig. 3b, inset).
ADP binding to myosin-7a in the presence and absence
of F-actin
To investigate ADP binding to myosin-7a, we used the
ﬂuorescent nucleotide analogue mantADP. Binding of
mantADP to myosin was performed under pseudo ﬁrst-
order conditions by mixing myosin (0.125 lM) with
varying concentrations of mantADP in a stopped-ﬂow
apparatus. The time course of the binding reaction was
monitored by observing the exponential increase in ﬂuo-
rescence. The observed rate constants are linearly
dependent on [mantADP] over the range from 0.5–4.5 lM.
The slope of the plot shown in Fig. 4a gives a second order
binding rate constant k?D of 0.98 ± 0.05 lM
-1 s
-1. The
dissociation rate constant k-D = 0.27 ± 0.01 s
-1 was
deduced from the ordinate intercept.
Mixing of 0.125 lM acto•M7a with excess amounts of
mantADP resulted in ﬂuorescence signals that could be
ﬁtted with a double-exponential function. Over the con-
centration range from 0.5–10 lM, the observed rate
constant for the fast phase is linearly dependent on the
concentration of nucleotide. In contrast, amplitude and rate
do not change over the same range for the slow phase. As
the slow phase makes only a minor contribution to the
overall signal and due to its invariance, we have not con-
sidered it during data analysis. Linear approximations of
the data of the fast phase give an apparent second order rate
constant k1AD of 1.78 ± 0.04 lM
-1s
-1 (Fig. 5a). Extrap-
olation of the line to zero [mantADP] indicates a
dissociation rate constant k2AD of 0.59 ± 0.03 s
-1.
ADP dissociation from myosin-7a in the absence
and presence of F-actin
The rate of ADP dissociation from myosin was measured
by monitoring the decrease in ﬂuorescence upon dis-
placement of mantADP from M7a with excess ATP. A
single-exponential approximation to the observed decrease
in the ﬂuorescence signal gives a rate constant k-D of
0.20 ± 0.01 s
-1 (data not shown). Alternatively, we fol-
lowed the dissociation of the M7a•ADP complex by the
displacement of ADP with excess ATP. A single-expo-
nential approximation to the observed increase in the
intrinsic protein ﬂuorescence signal gives a rate constant
k-D of 0.300 ± 0.002 s
-1 (Fig. 4b).
We determined the rate of displacement of ADP from
acto•M7a by monitoring the exponential decrease of the
light scattering signal that follows the addition of excess
ATP. A value of 0.48 ± 0.01 s
-1 was obtained for the
dissociation rate constant k2AD (Fig. 5b). Alternatively,
the dissociation rate constant was determined by chasing
the preincubated acto•M7a•mantADP complex with
excess ATP and following the monophasic decrease in the
ﬂuorescence signal. A value of 0.32 ± 0.01 s
-1 was
obtained for the k2AD using this approach (data not
Fig. 4 ADP interaction. a mantADP binding to the myosin-7a motor
domain. A linear approximation of the data set gives the second order
rate constant k?D = 0.98 ± 0.05 lM
-1 s
-1. Inset, time course of
mantADP (1 lM) binding to M7a (0.125 lM) in a stopped-ﬂow
apparatus. A single exponential ﬁt to the time course gives
kobs = 1.37 s
-1. The corresponding residual plot has the same time
axes as the ﬁt. b ADP release from M7a. Time course of the change in
ﬂuorescence intensity for the displacement of ADP (500 lM) from
0.25 lM with 1,500 lM ATP in the stopped-ﬂow apparatus. The
change in intrinsic tryptophan ﬂuorescence was ﬁtted using a single
exponential function, giving a value of 0.3 ± 0.002 s
-1 for k-D. The
residual plot (inset) and the ﬁt have the same time axes. c Competitive
binding of ATP and ADP to M7a. The time course in the absence of
ADP was ﬁtted by a single exponential function, whereas the time
courses in the presence of ADP were ﬁt to bi-exponentials. The
dependence of the observed amplitudes of the slow phase increases
with increasing [ADP]. A hyperbolic ﬁt of the data set resulted in a
KD of 0.52 ± 0.09 lM. Error bars represent standard deviations from
at least three determinations of each data point
c
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123shown). The determined rate constants are in good
agreement and similar to those reported previously by
Watanabe and coworkers [37] (Table 2). As the kinetics
of ADP binding and release are not greatly changed in the
presence of saturating concentrations of F-actin (k?-
D & k1AD; k-D & k2AD), the thermodynamic coupling
between the afﬁnity of myosin for ADP and F-actin (KAD/
KD & 1.2) is weak (Table 2). The value of k2AD is close
to the maximum steady-state cycling rate in the presence
of saturating F-actin (kcat), indicating that this step is rate
limiting in the pathway (kcat & k2AD).
ADP afﬁnity in the presence and absence of F-actin
The dissociation equilibrium constant for ADP binding to
actomyosin (KAD) was calculated to be 0.3 ± 0.22 lM
from the ratio of the binding and dissociation rate con-
stants KAD = k2AD/k1AD. By analogy, the dissociation
equilibrium constant in the absence of F-actin
KD = 0.27 ± 0.03 lM was calculated from the ratio k-D/
k?D. An experimental method of determining KD is the
displacement of ADP from myosin by the addition of
Fig. 5 ADP interaction of acto•M7a. a ADP binding to acto•M7a.
Linear approximation of the data set gives the second order rate
constant of mantADP binding to actomyosin-7a k1-
AD = 1.78 ± 0.04 lM
-1 s
-1. The corresponding intercept deﬁnes
k-AD = 0.59 ± 0.03 s
-1. Error bars represent standard deviations
from at least three determinations of each data point. b ADP
dissociation from acto•M7a. Displacement of ADP (1 lM) from
0.25 lM acto•M7a with excess ATP (1,000 lM). Single exponential
approximation of the decrease in light scattering signal gives
k2AD = 0.48 ± 0.01 s
-1. The corresponding residual plot (inset)
comprises the same time axes as the data ﬁt
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123excess ATP. Similar to the behavior of Dd myosin-2 [41],
ATP binding to M7a produces a larger increase in the
intensity of the intrinsic protein ﬂuorescence signal than
binding of ADP. In the assay, myosin was preincubated
with increasing concentrations of ADP and rapidly mixed
with ATP. The change of the intrinsic ﬂuorescence signal
was mono-exponential in the absence of ADP. In the
presence of ADP, the observed ﬂuorescence transients
were biphasic and could be described by double-expo-
nential ﬁts. This behavior is compatible with a kinetic
model in which the amplitude of the fast phase represents
ATP binding to free myosin, whereas the amplitude of the
slow phase is governed by the release of ADP from
M•ADP. As [ADP] was increased, the observed relative
amplitude of the slow phase increased. The [ADP]
dependence of the relative amplitude of the slow phase
(Aslow/Aslow ? Afast) on [ADP] is hyperbolic, giving the
dissociation equilibrium constant KD = 0.52 ± 0.09 lM
(Fig. 4c).
Magnesium sensitivity
Changes in the concentration of free Mg
2? ions affect the
ADP release kinetics from actomyosin. The observed rate
constants for the displacement of ADP from acto•M7a by
competition with ATP show a sigmoidal dependence on the
concentration of free Mg
2? ions (Fig. 6a). Increasing the
level of free Mg
2? ions within the range from 0.01 to
19 mM reduces the apparent rate of ADP release about
ﬁvefold from 0.92 to 0.20 s
-1. The apparent inhibition
constant Ki = 0.29 ± 0.03 mM lies within the intracellular
range of free Mg
2?-ion concentrations. In agreement with
our previous interpretation of the data, indicating that ADP
release from actomyosin is the rate-limiting step in the
actomyosin ATPase cycle, Mg
2? sensitivity deﬁnes the
actin-activated steady-state ATPase activity of human
myosin-7a in a dose-dependent manner. As depicted in
Fig. 6b, Mg
2? deprivation increased the steady-state turn-
over 3.5-fold. The inhibitory constant Ki is 291 lM,
corresponding to the value determined from the ADP
release experiments.
Myosin-7a motor activity
The functional competence of the recombinant myosin
motor domain construct was demonstrated in the in vitro
motility assay [23]. Analysis of the velocity of ﬂuorescent-
labeled actin ﬁlaments over a myosin-decorated glass
surface gives a mean velocity of *97 nm s
-1 at free
Mg
2?-ion concentrations smaller than 0.2 mM. Filament
movement ceases completely at concentrations of free
Mg
2? greater than 1 mM (data not shown).
Discussion
Here, we describe in detail the kinetic and functional
properties of the human myosin-7a motor domain. A
deﬁning feature of the myosin-7a actin-activated ATPase
cycle is the rate-limiting ADP release step. This is indic-
ative for the time the motor spends in the strongly bound
actomyosinADP state and hence a high duty ratio. The
thermodynamic coupling of ADP and F-actin binding or
the extent to which saturating concentrations of F-actin
accelerate the release of ADP deﬁnes the speciﬁc adapta-
tion of a myosin for its particular cellular function. In case
of myosin-7a, the coupling between actin and nucleotide
Fig. 6 Mg
2?sensitivityofacto•M7a.(A)InhibitionoftherateofADP
dissociationfromacto•M7abyfreeMg
2?.Increasingtheconcentration
offreeMg
2?ionswithintherangebetween0.01and19 mMsuppresses
ADP release kinetics ﬁvefold with a Ki = 0.29 ± 0.03 mM. The data
wereﬁttedtothefollowingequationk2AD = (kmin(Mg
2?/Ki) ?kmax)/
((Mg
2?/Ki) ? 1). b Inhibitory effect of free Mg
2? ions on the actin-
activated steady-state ATPase activity at 40 lM F-actin. The data set
was ﬁtted to a hyperbolic function resulting in a Ki of 0.29 mM. Error
bars represent standard deviations from at least three determinations of
each data point
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123binding (KAD/KD * 1.2) is weak. Consistently, ADP
release is weakly accelerated in the presence of F-actin
(k2AD/k-D * 1.1–1.8). Under the assumption that human
myosin-7a has a load-dependent ADP release, the kinetic
properties are compatible with myosin-7a acting as tension
sensor, as deﬁned by Nyitrai and Geeves [29].
Table 2 summarizes the kinetic constants of human
myosin-7a together with those from rodent and Drosophila
orthologues. The comparison of human myosin-7a with
other class-7 orthologues shows that all myosin-7 motors
display slow ATP turnover in combination with a high
afﬁnity for F-actin. An exceptional case is Drosophila
myosin-7b, which shows both, a faster steady-state ATPase
and lower afﬁnity for F-actin in the presence and absence
of ADP. As listed in Table 1, the coupling efﬁciency
between the nucleotide binding site and the F-actin binding
region (kcat/Kapp, actin) is low for human, mouse, and rat
myosin-7a (96–97% sequence identity within the motor
domain) and elevated for the Drosophila myosins-7a and
-7b and murine myosin-7b (sequence identity 56–65% with
the human myosin-7a motor domain). A rate-limiting ADP
release step from actomyosin and high duty ratios seem to
be common features of class-7 myosins from different
species qualifying these motors to participate in tension-
mediating processes (Table 2). Furthermore, a speciﬁc
attribute of class-7a myosins is an up to 25-fold reduced
ATP hydrolysis rate k3 ? k-3 when compared with class
7b myosins. In this context, Drosophila myosin-7a is
unique since it hydrolyzes ATP predominantly while bound
to F-actin [42] (Table 2).
Kinetic studies performed with unconventional myosins
from classes 1 and 5 revealed that the steady-state ATPase
and ADP release rates are inhibited by free Mg
2? in the
upper physiological range, indicating that ADP leaves the
catalytic site via a Mg
2?-dependent mechanism [24, 34, 43,
44]. Our results show that magnesium ions act as modu-
lators of myosin-7a motor activity. Changes in the level of
free Mg
2? ions within the physiological range affect ADP
release kinetics from actomyosin-7a. At low Mg
2?-ion
concentrations, fast ADP dissociation occurs. High con-
centrations of free Mg
2? slow the release of ADP and
consequently stabilize the tension-bearing actomyo-
sinADP state. Since ADP release is the rate-determining
step in the ATPase cycle, excess free Mg
2? ions do affect
the steady-state turnover of ATP. The inhibitory constant
of Ki = 291 lM lies in the lower range of cytosolic free
Mg
2? ion concentrations.
Assuming that changes in the concentration of free
Mg
2? ions affect primarily ADP release kinetics and to a
much smaller extent ADP-binding kinetics, KAD is mag-
nesium sensitive and decreases with increasing Mg
2?.T h i s
assumption is in good agreement with the observation that
the in vitro sliding velocity is Mg
2? ion dependent. The
Mg
2? sensitive ADP release activity of myosin-7a resem-
bles that found in other unconventional myosins. Previous
studies proposed a model in which Mg
2? ion sensitivity is
relevant for myosins that display a strain-dependent ADP
dissociation step associated with an additional movement
of the lever arm [43, 45]. Henn and coworkers speculate
that murine myosin-7b undergoes a rotation of the regu-
latory domain and a load-dependent ADP release [46].
Therefore, it is conceivable that the Mg
2? ion sensitivity of
human myosin-7a follows the same mechanism.
Taken together, the main properties of human myosin-
7a are a rate-limiting and Mg
2? ion-sensitive ADP-release
step from actomyosin, high afﬁnities for ADP and F-actin,
and a low degree of coupling between the actin- and
nucleotide-binding sites. These speciﬁc kinetic adaptations
indicate that human myosin-7a is a slow molecular motor
with a high duty ratio, suitable for moving cargoes and
mediating tension in the cytoskeleton. Spatio-temporal
ﬂuctuations in the cytosolic concentration of free Mg
2?
ions are likely to enable this molecular motor to switch
between cargo-moving and tension-bearing modes.
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